Roland E Kontermann Selected Research

ErbB Receptors (EGF Receptor)

1/2022	The eIg technology to generate Ig-like bispecific antibodies.
1/2021	A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells.
1/2017	Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV.
10/2014	A fusogenic dengue virus-derived peptide enhances antitumor efficacy of an antibody-ribonuclease fusion protein targeting the EGF receptor.
10/2012	The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity.
6/2009	Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Roland E Kontermann Research Topics

Disease

76	Neoplasms (Cancer) 03/2024 - 08/2003
6	Melanoma (Melanoma, Malignant) 12/2022 - 01/2004
6	Neoplasm Metastasis (Metastasis) 12/2022 - 06/2012
6	Inflammation (Inflammations) 09/2021 - 02/2010
4	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2024 - 10/2019
4	Breast Neoplasms (Breast Cancer) 01/2021 - 11/2010
4	Fibrosarcoma 01/2018 - 03/2015
3	Neuralgia (Stump Neuralgia) 01/2024 - 01/2019
3	Multiple Sclerosis 01/2024 - 10/2019
3	Demyelinating Diseases (Demyelinating Disease) 04/2023 - 10/2019
3	Necrosis 04/2023 - 01/2019
3	Head and Neck Neoplasms (Head and Neck Cancer) 10/2014 - 11/2010
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2023 - 10/2016
2	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 02/2018
2	Glioblastoma (Glioblastoma Multiforme) 12/2021 - 11/2018
2	Rheumatoid Arthritis 01/2021 - 04/2008
2	Fibrosis (Cirrhosis) 01/2020 - 09/2015
2	Communicable Diseases (Infectious Diseases) 03/2012 - 10/2004
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2010 - 06/2010
2	Carcinoma (Carcinomatosis) 05/2004 - 12/2003
1	Hypersensitivity (Allergy) 01/2024
1	Hepatitis D 10/2023
1	Memory Disorders (Memory Loss) 01/2023
1	Neuroinflammatory Diseases 01/2023
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022
1	Central Nervous System Diseases (CNS Diseases) 09/2021
1	Wilms Tumor (Wilm's Tumor) 01/2021
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2021
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2021
1	Stomach Neoplasms (Stomach Cancer) 01/2021
1	Neoplasm Micrometastasis 11/2020
1	Non-alcoholic Fatty Liver Disease 01/2020
1	Fatty Liver 01/2020
1	Insulin Resistance 01/2020
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2020

Drug/Important Bio-Agent (IBA)

29	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2004
16	AntigensIBA 01/2023 - 01/2004
14	Liposomes (Liposome)IBA 10/2020 - 05/2004
13	LigandsIBA 01/2022 - 06/2012
12	Type II Tumor Necrosis Factor ReceptorsIBA 01/2024 - 10/2016
10	Bispecific AntibodiesIBA 03/2024 - 01/2005
10	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2023 - 07/2009
8	CytokinesIBA 04/2023 - 10/2008
8	Peptides (Polypeptides)IBA 01/2021 - 08/2003
7	Type I Tumor Necrosis Factor ReceptorsIBA 05/2023 - 10/2016
7	AntibodiesIBA 01/2021 - 10/2004
7	Immunoglobulin FragmentsIBA 10/2020 - 10/2008
7	EndoglinIBA 04/2020 - 03/2004
6	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2023 - 10/2016
6	ErbB Receptors (EGF Receptor)IBA 01/2022 - 06/2009
5	Phosphotransferases (Kinase)IBA 12/2022 - 01/2018
4	TNF-Related Apoptosis-Inducing LigandIBA 01/2022 - 05/2014
4	Immunoglobulin G (IgG)IBA 01/2021 - 01/2014
4	Single-Chain AntibodiesIBA 10/2014 - 07/2007
3	Immunoglobulins (Immunoglobulin)IBA 01/2022 - 05/2015
3	Epithelial Cell Adhesion MoleculeIBA 11/2020 - 01/2016
3	Coloring Agents (Dyes)IBA 10/2020 - 01/2017
3	Therapeutic UsesIBA 01/2020 - 01/2018
3	Interleukin-15 (Interleukin 15)IBA 01/2019 - 06/2012
3	Monoclonal AntibodiesIBA 10/2018 - 07/2005
3	ranpirnase (Pannon)IBA 05/2015 - 10/2014
3	Ribonucleases (Ribonuclease)IBA 05/2015 - 10/2014
2	Trastuzumab (Herceptin)FDA Link 01/2022 - 01/2017
2	Neuregulin-1 (Neuregulin 1)IBA 01/2022 - 01/2017
2	Death Domain ReceptorsIBA 12/2021 - 05/2014
2	Glutamic Acid (Glutamate)FDA Link 09/2021 - 01/2019
2	Granzymes (Granzyme)IBA 01/2021 - 08/2011
2	human ERBB2 proteinIBA 10/2020 - 10/2012
2	Fluorescent Dyes (Fluorescent Probes)IBA 10/2020 - 05/2016
2	EpitopesIBA 01/2020 - 01/2017
2	Tumor Biomarkers (Tumor Markers)IBA 01/2017 - 05/2015
2	Peptide Hydrolases (Proteases)FDA Link 07/2014 - 01/2005
2	Carcinoembryonic AntigenIBA 11/2010 - 09/2009
2	Small Interfering RNA (siRNA)IBA 06/2010 - 02/2010
2	Surface Antigens (Surface Antigen)IBA 11/2008 - 07/2007
1	Myelin ProteinsIBA 01/2024
1	Pertussis ToxinIBA 01/2024
1	Neutralizing AntibodiesIBA 10/2023
1	Myelin-Oligodendrocyte GlycoproteinIBA 04/2023
1	N-Methylaspartate (NMDA)IBA 01/2023
1	Focal Adhesion Protein-Tyrosine KinasesIBA 12/2022
1	Immunoconjugates (Immunoconjugate)IBA 01/2022
1	Cetuximab (Erbitux)FDA Link 01/2022
1	Prolactin Receptors (Prolactin Receptor)IBA 01/2022
1	histidine-rich proteinsIBA 01/2022
1	Immunoglobulin M (IgM)IBA 01/2022
1	Immunoglobulin E (IgE)IBA 01/2022
1	Angiopep-2IBA 12/2021
1	CuprizoneIBA 09/2021
1	Doxycycline (Periostat)FDA LinkGeneric 01/2021
1	Histocompatibility Antigens Class IIBA 01/2021
1	Proteolysis Targeting ChimeraIBA 01/2021
1	Interleukin-10 (Interleukin 10)IBA 11/2020
1	pembrolizumabIBA 01/2020
1	Alanine Transaminase (SGPT)IBA 01/2020
1	Triglycerides (Triacylglycerol)IBA 01/2020
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020

Therapy/Procedure

40	Therapeutics 03/2024 - 01/2004
12	Immunotherapy 01/2022 - 08/2007
3	Drug Therapy (Chemotherapy) 01/2020 - 02/2006